These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29095283)

  • 1. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
    Chen C; Chen T; Huang C; Wang J; Fei Z
    Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
    Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
    Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
    Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
    Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
    Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    He X; Ou D; Ying H; Zhu G; Hu C; Liu T
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1027-33. PubMed ID: 21706324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
    Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
    Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue.
    Niu X; Chang X; Gao Y; Hu C; Kong L
    Radiat Oncol; 2013 Oct; 8():226. PubMed ID: 24083351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
    Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
    BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.
    Guan Y; Liu S; Wang HY; Guo Y; Xiao WW; Chen CY; Zhao C; Lu TX; Han F
    Chin J Cancer; 2016 Feb; 35():20. PubMed ID: 26879049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.